BioWorld22h
Just one more vote to go for FDA, NIH nominees
As expected, the U.S. Senate Health, Education, Labor and Pensions Committee voted March 13 to send the nominations of Jay ...
BioWorld3h
In HIV, draining the reservoir means understanding the brain
The availability of effective antiretroviral therapy has lowered the risk, and the severity, of neural sequelae of HIV infection. “Early in the HIV pandemic, approximately 15% of people with HIV had ...
BioWorld20h
Endo the line: Mallinckrodt merger worth $6.7B
The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...
BioWorld20h
With warming market, Hinge swings back to IPO
After scrapping plans for an IPO in 2022, Hinge Health Inc. is taking a more favorable view of going public given the increased support seen for health care and med-tech stocks in recent months. The ...
BioWorld1d
Vivani looking to get slim with Cortigent neurostimulation spin
The Vivani Medical Inc. combination appears to be over less than three years since its inception after the company reported ...
BioWorld1d
First-in-class oral immunomodulator shows efficacy in psoriasis models
Psoriasis is a chronic, recurrent and inflammatory skin disorder associated with immune system dysregulation. The abnormal ...
BioWorld1d
Rakovina advances ATR inhibitors into preclinical testing
Rakovina Therapeutics Inc. has received the first synthesized batch of AI-generated ATR inhibitor compounds developed in ...
BioWorld1d
Australian patient first to leave hospital with Bivacor TAH
An Australian man in his 40s with severe heart failure was implanted with a Bivacor Inc. total artificial heart (TAH) and has been discharged from the hospital. He remained at home with the artificial ...
BioWorld1d
AMP says FDA asks too much of test validation in Section 564 draft
The U.S. FDA’s January 2025 draft guidance for test validation in public health emergencies drew only six responses, but pointed responses they were, indeed. As an example, the Association for ...
BioWorld1d
Adenine base editing corrects G542X mutation in CFTR in patient organoid models
Cystic fibrosis (CF) is a life-threatening autosomal recessive disease affecting over 160,000 people worldwide. CF is caused by loss-of-function mutations in the CF transmembrane conductance regulator ...
BioWorld1d
OC-STAMP identified as a potential diagnostic biomarker and therapeutic target for silicosis
Silicosis, resulting from prolonged exposure to free crystalline silica dust, is an occupational disease characterized by silica nodules and extensive lung tissue fibrosis. The etiology of silicosis ...
BioWorld1d
Preclinical data reported for LETI-101 show allele selective editing and mHTT reduction
Researchers from Life Edit Therapeutics Inc. recently reported preclinical data on the application of their gene editing technology Life Edit CRISPR system to Huntington’s disease (HD).